超声LI-RADS US-3类观察的结局:多期MRI/CT或病理验证
该回顾性研究纳入267例HCC高危患者,筛查US按US LI-RADS归为US-3类,其中81.6%有后续多期MRI/CT或病理证实。US-3对可能或明确HCC的PPV为18.8%,对任何恶性肿瘤的PPV为20.6%,支持现行指南对US-3行进一步多期横断面影像评估。
要点
- US-3类观察中约1/5最终证实为可能或明确HCC。
- US-3最常见原因为≥1cm可测肿块(88.8%)。
- US-3需按指南行多期MRI/CT进一步评估。
核心结论
- 在HCC筛查人群中,约1/5的US-3类观察在多期MRI/CT或病理上代表可能或明确HCC。
- 研究结果支持现行US LI-RADS指南对US-3类观察行进一步多期横断面影像评估。
研究设计与样本
- 回顾性分析纳入267例HCC高危患者(男161例、女106例,平均年龄58.6±12.2岁),于2017年1月至2019年6月行筛查肝脏US。
- US-3类观察基于US LI-RADS算法在前瞻性临床基础上判定,随访分析后续影像和/或病理结果。
- 81.6%(218/267)患者有可用的多期增强MRI或CT或病理证实检查。
关键影像表现/征象
- US可视化评分A占40.8%(109/267)、B占52.8%(141/267)、C占6.4%(17/267)。
- US-3原因为≥1cm可测肿块者占88.8%(237/267),平均大小1.8±1.0cm,范围1.0-6.9cm。
- US-3原因为≥1cm实质扭曲区者占7.9%(21/267),平均大小1.8±0.9cm,范围1.0-4.0cm;新发静脉血栓者占3.4%(9/267)。
- 后续MRI/CT或病理原因:无异常41.3%(90/218)、良性病变32.6%(71/218)、LR-3 5.5%(12/218)、LR-4或LR-5或病理HCC 18.8%(41/218)、LR-M或其他恶性肿瘤1.8%(4/218)。
诊断标准与关键数值
- US-3类观察对可能或明确HCC的PPV为18.8%。
- US-3类观察对任何恶性肿瘤的PPV为20.6%。
临床应用与阅片要点
- 筛查US发现US-3类观察时,应按指南建议行多期增强MRI或CT进一步评估。
- US-3类观察中约4成后续MRI/CT无异常,阅片时需注意假阳性可能。
局限性
- 本研究为单中心回顾性分析。
- 仅81.6%患者有后续多期MRI/CT或病理证实,存在验证偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of the study is to evaluate the outcomes of ultrasound (US) LI-RADS category US-3 observations detected at US performed for hepatocellular carcinoma (HCC) screening and surveillance on the basis of subsequently performed multi-phase MRI or CT or histopathology. MATERIALS AND METHODS. In this retrospective analysis, 267 patients at high risk for HCC (161 men and 106 women; mean [± SD] age, 58.6 ± 12.2 years) underwent screening liver US between January 2017 and June 2019 and were assigned US-3 observations on a prospective clinical basis using the US LI-RADS algorithm. The results of follow-up imaging studies and/or histopathology were analyzed. RESULTS. Visualization scores assigned at US were A (40.8% [109/267]), B (52.8% [141/267]), and C (6.4% [17/267]). Reasons for US-3 observations included a measurable mass of 1 cm or larger (88.8% [237/267]; mean size, 1.8 ± 1.0 cm; range, 1.0-6.9 cm), an area of parenchymal distortion of 1 cm or greater (7.9% [21/267]; mean size, 1.8 ± 0.9 cm; range, 1.0-4.0 cm), or a new venous thrombus (3.4% [9/267]). Confirmatory testing with multiphase contrast-enhanced MRI or CT or with histopathology was available for 81.6% (218/267) of patients. Causes of US-3 observations included no abnormality at MRI or CT (41.3% [90/218]), a benign lesion (32.6% [71/218]), a LI-RADS category 3 (LR-3) observation at MRI or CT (5.5% [12/218]), a LI-RADS category 4 or 5 (LR-4 or LR-5) observation at MRI or CT or identification of HCC at histopathology (18.8% [41/218]), and an LR-M (denoting probably or definitely malignant but without specific features for HCC) observation at MRI or CT or other malignancy at histopathology (1.8% [4/218]). The PPV of a US-3 observation for probable or definite HCC was 18.8%, and for any malignancy it was 20.6%. CONCLUSION. In the HCC screening population, approximately one in five US-3 observations represents probable or definite HCC at multiphase MRI or CT or HCC at histopathology. These findings support current US LI-RADS guidelines to pursue further evaluation with multiphase cross-sectional imaging for US-3 observations.
引用
- Sevco TJ, Masch WR, Maturen KE, et al. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol. 2021. PMID: 34259543. doi:10.2214/AJR.20.23447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。